Symptomdx.

Get Started

Delayed Hemolytic Transfusion ReactionMANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

746 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp49

Immediate recognition

›Critical triggers for DHTR

›Hemoglobin decline below pretransfusion level 3-30 days after RBC transfusion

›Hallmark of hyperhemolysis syndrome

›Destruction of both transfused and autologous RBCs

›Hemoglobinuria (dark/cola-colored urine) with worsening anemia

›Intravascular hemolysis component

›Renal injury risk if persistent

›Fever, jaundice, back or flank pain post-transfusion

›Symptom onset typically 3-30 days post-transfusion

›Median onset approximately 8 days in pediatric SCD

Resuscitation priorities

›Airway and oxygenation

›Supplemental oxygen for SpO2 < 94%

›High-flow oxygen for acute chest syndrome overlap

›SpO2 target 94-98% in non-SCD

›Escalate to ICU if hemodynamic instability or severe anemia with hemoglobin < 50 g/L

›Cardiovascular compromise from demand ischemia

›Multiorgan dysfunction risk

›Circulation and hemodynamics

›IV access with two large-bore peripheral IVs

›Fluid resuscitation to maintain urine output >= 0.5-1 mL/kg/hr

›Normal saline or lactated Ringer's preferred

›Vasopressor support if MAP < 65 mmHg despite volume

›Norepinephrine first-line for distributive shock

›Target MAP >= 65 mmHg

Critical pitfalls

›NEVER administer additional RBC transfusion in active hyperhemolysis

02History/hx83

Transfusion history

›Recent RBC transfusion context

›Timing of most recent transfusion

›Symptom onset 3-30 days post-transfusion is characteristic

›Onset > 30 days makes DHTR less likely

›Number of units transfused and indication

›Chronic transfusion programs (SCD, thalassemia) carry highest risk

›Single episodic transfusions also at risk

›Facility where transfusion occurred

›Outside facility record fragmentation major risk factor

›Prior antibody identification cards may be missing

›Alloimmunization history

›Prior known RBC alloantibodies

›25% of alloantibodies become undetectable within 10 months

›Previously negative screen does not exclude sensitization

›Lifetime transfusion history

›Cumulative antigen exposure increases alloimmunization risk

›Multiple prior reactions suggest high-responder phenotype

›Obstetric history in female patients

›Fetal-maternal hemorrhage as alloimmunization source

›Number of pregnancies relevant to sensitization risk

Presenting symptoms

›Hemolysis symptom complex

›Dark, cola-colored, or red-brown urine

›Hemoglobinuria indicates significant hemolysis

›Oliguria suggests renal compromise

›Jaundice or scleral icterus

›Indirect bilirubin elevation from RBC breakdown

›Onset typically 3-10 days post-transfusion

›Fever and chills

›Low-grade to moderate fever typical

›High fever raises concern for concurrent infection

›Pain and systemic symptoms

›Back, flank, or abdominal pain

›Extravascular hemolysis in spleen and liver

›Renal capsule stretch from hemoglobinuria

›Chest pain and dyspnea

›Acute chest syndrome overlap in SCD

›Demand ischemia with severe anemia

›Fatigue and malaise

›Disproportionate to degree of visible jaundice

›Rapid hemoglobin decline drives symptom severity

Risk factors

›Underlying hematologic disease

›Sickle cell disease

›Highest risk population, incidence up to 11%

›DHTR frequently mimics vaso-occlusive crisis

›Thalassemia and other chronic transfusion-dependent anemias

›Lifelong transfusion exposure

›Multiple alloantibody accumulation

›Allogeneic stem cell transplant recipients

›Altered immune reconstitution post-transplant

›Mixed chimerism and antibody dynamics

›Sensitization risk factors

›Prior alloimmunization even if currently undetectable

›Anamnestic response on re-exposure

›No safe transfusion threshold once sensitized

›Pregnancy history

›Fetal-maternal hemorrhage sensitization route

›Anti-K, anti-D, anti-c most common in this context

›Inflammatory state at time of prior transfusion

›Acute illness amplifies immune response to foreign antigens

›Infection at time of transfusion increases alloimmunization risk

›Ethnic antigenic disparity between donor and recipient

›African-ancestry recipients at higher risk from predominantly Caucasian donor pool

›Rh and Kell variants more divergent across populations

Past medical history

›Medical background

›Known hemoglobinopathy type and severity

›SCD genotype (HbSS, HbSC, HbS-beta-thal)

›Thalassemia type and transfusion dependence

›Prior transfusion reactions

›Prior DHTR episodes indicate recurrence risk

›Prior acute hemolytic reactions

›Splenectomy status

›Alters extravascular hemolysis dynamics

›Reduces Howell-Jolly body clearance

›Autoimmune conditions

›May predispose to concurrent autoantibody formation

›Autoimmune hemolytic anemia overlap possible

›Medication review

›Daratumumab (anti-CD38 therapy)

›Interferes with serologic testing

›Can delay alloantibody detection

›Current immunosuppressive agents

›May modify immune response to hemolysis

›Consider steroid-related VOC risk in SCD

03Physical Exam/exam68

Vital signs

›Hemodynamic assessment

›Heart rate

›Tachycardia from anemia-driven compensatory response

›Persistent tachycardia despite oxygen indicates severe anemia

›Blood pressure

›Hypotension in severe or decompensated hemolysis

›MAP < 65 mmHg requires vasopressor consideration

›Temperature

›Low-grade fever typical of immune-mediated hemolysis

›High fever raises concurrent infection concern

›Respiratory rate

›Tachypnea from anemia or acute chest syndrome

›SpO2 on room air mandatory

Skin and mucous membranes

›Hemolysis signs

›Scleral icterus

›Indirect bilirubin accumulation

›Subtle finding requiring bright lighting

›Jaundice

›Generalized skin yellowing

›More visible in conjunctivae and oral mucosa

›Pallor

›Conjunctival pallor correlates with hemoglobin < 70 g/L

›Palmar pallor sensitive in dark-skinned patients

›Additional skin findings

›Petechiae or purpura if DIC component

›Check mucosal surfaces

04Differential Diagnosis/ddx50

Life-threatening mimics

›Immediately dangerous diagnoses

›Acute hemolytic transfusion reaction

›ICD-10 T80.30XA (hemolytic reaction, unspecified)

›Occurs during or within 24 hours of transfusion

›More dramatic with ABO incompatibility and intravascular hemolysis

›Sepsis with DIC

›ICD-10 A41.9

›Can mimic hemolytic reaction with hemolysis from microangiopathy

›Blood cultures, fever pattern, source identification

›Thrombotic thrombocytopenic purpura (TTP)

›ICD-10 M31.1

›Schistocytes, thrombocytopenia, renal dysfunction, neurologic changes

›ADAMTS13 level for confirmation

Hematologic mimics

›Hemolytic conditions

›Autoimmune hemolytic anemia (AIHA)

›ICD-10 D59.1

›Positive DAT without temporal relationship to transfusion

›Can coexist with DHTR

›Drug-induced hemolytic anemia

›Temporal relationship to medication, not transfusion

›Common culprits: cephalosporins, NSAIDs, quinidine

›G6PD deficiency exacerbation

›ICD-10 D55.0

›Oxidative stress trigger

›Heinz bodies on peripheral smear

›Delayed serologic transfusion reaction

05Laboratory Tests/lt66

Core hemolysis panel

›Complete blood count with differential

›Hemoglobin

›Decline below pretransfusion level is diagnostic hallmark

›Severity: mild >70 g/L, moderate 50-70 g/L, severe <50 g/L

›Reticulocyte count

›Reticulocytopenia during active hemolysis indicates marrow suppression

›Reticulocytosis in recovery phase

›Reticulocytopenia with severe hemolysis indicates worse prognosis

›Platelet count

›Thrombocytopenia raises DIC or TTP concern

›Baseline in SCD typically 350-500 x 10^9/L

›Hemolysis markers

›Lactate dehydrogenase (LDH)

›Elevated; median 2239 IU/L in pediatric SCD with DHTR

›Degree of elevation correlates with severity

›Indirect bilirubin

›Elevated in extravascular hemolysis

›Rapid rise differentiates hemolysis from liver disease

›Haptoglobin

›Low or undetectable in active hemolysis

›Sensitivity approximately 83% for hemolysis

›Peripheral blood smear

›Spherocytes and microspherocytes in extravascular hemolysis

›Schistocytes if microangiopathic component

Immunologic testing

›Blood bank workup

›Direct antiglobulin test (DAT)

06Diagnostic Tests/dt60

Scoring Systems

›DHTR severity stratification

›Mild to moderate DHTR criteria

›Unexplained hemoglobin drop without falling below pretransfusion level

›Jaundice and low-grade fever

›No hemoglobinuria

›Self-limited in most cases

›Severe DHTR (hyperhemolysis) criteria

›Hemoglobin falls below pretransfusion level

›Hemoglobinuria present

›Reticulocytopenia during active hemolysis

›Destruction of both transfused and autologous RBCs

›Critical hyperhemolysis features

›Hemoglobin < 50 g/L with hemodynamic compromise

›Multiorgan dysfunction (renal failure, acute chest syndrome, stroke)

›Warrants ICU admission and urgent immunosuppressive therapy

MRI

›Brain MRI indications in DHTR

›Neurologic symptoms in SCD patients

›Focal neurologic deficit, altered consciousness, severe headache

›SCD with severe anemia is a stroke risk state

›DWI sequences sensitive for acute ischemic stroke

›MRI brain preferred over CT for SCD stroke evaluation

›Superior sensitivity for posterior fossa and small cortical infarcts

›No ionizing radiation

›MRI abdomen if hepatic or splenic sequestration suspected

›Characterize organomegaly and perfusion

›Not first-line; ultrasound preferred initially

07Disposition/dispo59

Admission criteria

›Indications for inpatient admission

›Hemoglobin significantly below pretransfusion level

›Hyperhemolysis pattern requires close monitoring

›Trend determination requires serial inpatient labs

›Active hemoglobinuria

›Renal protection requires IV fluids and output monitoring

›Cannot be reliably managed as outpatient

›Symptomatic anemia

›Tachycardia, dyspnea, chest pain, altered mental status

›Any hemoglobin < 50 g/L

›SCD patient with overlapping VOC or acute chest syndrome

›Complex management requiring specialized nursing

›Pain crisis management protocols

›Need for immunosuppressive therapy

›IVIg or corticosteroid administration

›Eculizumab initiation and monitoring

ICU criteria

›ICU admission triggers

›Hemodynamic instability

›SBP < 90 mmHg or MAP < 65 mmHg

›Vasopressor requirement

›Severe anemia with hemoglobin < 50 g/L and symptoms

›High risk of cardiovascular decompensation

›Continuous monitoring required

›Multiorgan dysfunction

›Acute kidney injury with oliguria

›Acute chest syndrome requiring oxygen > 4 L/min

08Treatment/t84

Immediate stabilization

›Stop-transfusion protocol

›Halt all ongoing transfusions immediately

›Notify blood bank and transfusion medicine

›Retain residual blood unit and tubing for testing

›IV fluid resuscitation

›Normal saline 500 mL bolus for hemodynamic compromise

›Maintenance rate 1-1.5x maintenance to force urine output

›Target urine output >= 0.5-1 mL/kg/hr to prevent hemoglobin cast nephropathy

›Supplemental oxygen

›Titrate to SpO2 >= 94%

›High-flow nasal cannula if acute chest syndrome

Treatment for mild DHTR (no hyperhemolysis)

›Supportive management

›Monitoring only in stable patients with mild hemoglobin decline

›Serial CBC every 12-24 hours

›Most resolve spontaneously within 1-2 weeks

›Antigen-matched RBC transfusion if hemoglobin support needed

›Extended antigen-matched units (C/c, E/e, K, Jka/Jkb, Fya/Fyb, S/s)

›Only transfuse if hemoglobin drop is symptomatic

›Crossmatch against specific identified alloantibody

›Supportive erythropoiesis

›Folic acid 1-5 mg orally daily

›Iron supplementation only if deficiency confirmed

›Vitamin B12 if deficiency identified

Treatment for severe DHTR with hyperhemolysis (ASH 2020 Guidelines)

›First-line immunosuppressive therapy

›Intravenous immunoglobulin (IVIg)

›Dose: 0.4-1 g/kg/day IV over 4-8 hours

›Duration: 3-5 consecutive days

›Total dose up to 2 g/kg per course

›Mechanism: Fc receptor blockade reducing macrophage phagocytosis of RBCs

›Corticosteroids concurrent with IVIg

›Methylprednisolone 1-4 mg/kg/day IV in divided doses

›Alternative: Prednisone 1-4 mg/kg/day orally if tolerating PO

›Duration: 3-5 days then taper over 1-2 weeks

›Caution: Taper carefully in SCD patients to avoid precipitating VOC

›Second-line: eculizumab

›Indications

›Failure of IVIg and corticosteroids

›Complement-mediated hyperhemolysis

›Rapidly worsening hemolysis despite first-line therapy

›Dosing

›Adults > 40 kg: 900-1200 mg IV weekly

›Weight-based dosing for pediatric patients per manufacturer guidance

›Administer over 35 minutes as IV infusion

›Prerequisite requirements

›Meningococcal vaccination (MenACWY and MenB) at least 2 weeks before initiation

›If urgent, vaccine same day with ciprofloxacin 500 mg orally twice daily prophylaxis

›Ciprofloxacin continued for minimum 2 weeks post-vaccination

›Mechanism

›Terminal complement C5 inhibitor

›Blocks membrane attack complex formation

›Evidence level: Class IIb, case series and retrospective data

›Rituximab for alloantibody prevention

›Primary indication: Prevention of additional alloantibody formation

›Consider when future transfusions anticipated

›Not first-line for acute hemolysis treatment

›Dosing

›375 mg/m2 IV weekly for 4 doses (standard lymphoma protocol)

›Single dose protocols used in some case series

›Timing

›After acute hemolysis is controlled

›B-cell depletion requires 2-4 weeks to reach maximum effect

Supportive erythropoiesis

›Stimulating bone marrow recovery

›Erythropoietin (EPO) stimulating agents

›Epoetin alfa 150-300 units/kg subcutaneously 3 times weekly

›Alternative: Darbepoetin 0.45-4.5 mcg/kg subcutaneously weekly

›Target hemoglobin recovery without triggering hyperviscosity

›Iron supplementation

›IV iron sucrose 200 mg IV over 60 minutes

›Only if iron stores depleted (ferritin < 100 mcg/L)

›Most chronically transfused patients are iron overloaded

›Folic acid

›1-5 mg orally daily for hemolytic states

›Supports erythropoiesis during recovery

Transfusion management if absolutely required

›Indications for transfusion despite DHTR

›Life-threatening anemia with hemodynamic compromise

›Hemoglobin < 30-40 g/L with cardiovascular instability

›Stroke or acute coronary syndrome from anemia

›Extended antigen-matched RBC protocol

›Minimum: Rh (C/c, E/e) and K antigen matching

›Ideal: Also match Jka/Jkb, Fya/Fyb, S/s antigens

›Electronic crossmatch against all identified alloantibodies

›Transfuse slowly with close monitoring

›Rate 1 mL/kg/hr or slower

›Reassess hemolysis markers 2-4 hours post-transfusion

09Special Populations/sp62

Pregnancy

›DHTR in pregnancy

›Increased alloimmunization risk

›Fetal-maternal hemorrhage during pregnancy sensitizes to fetal RBC antigens

›Anti-D, anti-K, anti-c most clinically significant for fetal risk

›Rh immune globulin prevents D sensitization but not other antigen sensitization

›Hemolytic disease of the fetus and newborn (HDFN) risk

›Maternal alloantibodies cross placenta via IgG transport

›Anti-K particularly dangerous to fetal erythropoiesis

›Fetal monitoring required with identified maternal alloantibodies

›Management in pregnancy

›Multidisciplinary: hematology, maternal-fetal medicine, transfusion medicine

›IVIg relatively safe in pregnancy (Category C equivalent)

›Eculizumab: limited data, case reports in paroxysmal nocturnal hemoglobinuria in pregnancy suggest relative safety

›Corticosteroids: generally safe in pregnancy; betamethasone preferred for fetal lung maturity

›Blood product selection

›Extended antigen-matched RBCs mandatory in pregnancy

›CMV-negative, irradiated if immunocompromised

›Hemoglobin targets

›Target hemoglobin >= 80 g/L in pregnancy for fetal oxygen delivery

›Avoid hyper-transfusion and hyperviscosity

Geriatric

›DHTR in older adults

›Altered presentation

›Tachycardia may be blunted by beta-blocker use

›Hemoglobin decline better tolerated hemodynamically initially then sudden decompensation

›Jaundice may be attributed to other causes and delay diagnosis

›Comorbidity burden

›Cardiac disease reduces tolerance to rapid hemoglobin decline

›Renal insufficiency at baseline increases hemoglobin nephrotoxicity risk

›Polypharmacy interactions with immunosuppressive therapy

›Drug dosing modifications

›IVIg: standard dosing; monitor renal function (osmotic nephropathy risk)

›Corticosteroids: increased risk of hyperglycemia, delirium, and osteoporosis

›Eculizumab: no dose adjustment required for age alone

›Transfusion threshold modifications

›Lower transfusion threshold for symptomatic anemia in cardiac disease

›Target hemoglobin >= 80 g/L for known coronary artery disease

›Transfuse slowly to avoid volume overload

Pediatrics

›DHTR in children

›Epidemiology in pediatric SCD

›Incidence up to 11% in pediatric SCD patients

›Median symptom onset approximately 8 days post-transfusion

›Median LDH 2239 IU/L in pediatric SCD with DHTR

›Presentation differences

›Hyperhemolysis more commonly reported in pediatric SCD

›Reticulocytopenia during active hemolysis is a key feature

›VOC/DHTR overlap particularly common in younger patients

›Weight-based dosing

›IVIg: 0.4-1 g/kg/day IV for 3-5 days (same per-kg dose as adults)

›Methylprednisolone: 1-4 mg/kg/day IV divided every 6-12 hours

›Eculizumab pediatric dosing: weight-based per manufacturer

›5 to < 10 kg: 300 mg weekly x2 then 300 mg every 3 weeks

›10 to < 20 kg: 600 mg weekly x2 then 300 mg every 2 weeks

›20 to < 30 kg: 600 mg weekly x2 then 600 mg every 2 weeks

›30 to < 40 kg: 900 mg weekly x2 then 900 mg every 2 weeks

›>= 40 kg: 900-1200 mg weekly (adult dosing)

›Meningococcal prophylaxis in pediatric eculizumab use

›Age-appropriate meningococcal vaccine schedule required

›Antibiotic prophylaxis until 2 weeks after vaccination confirmed

›Chronic transfusion program considerations

›Extended phenotype matching from first transfusion recommended

›Prevents incremental alloantibody accumulation

›ASH 2020 guidelines recommend Rh and Kell antigen matching for all SCD patients

10Background/b84

Epidemiology

›Incidence and prevalence

›General population incidence

›Approximately 1 per 2,500 RBC transfusions in general population

›Estimated 1,200-1,400 cases per year in the United States

›High-risk population incidence

›Sickle cell disease: incidence up to 11% per transfusion episode

›Up to 30% lifetime prevalence in multiply transfused SCD patients

›Thalassemia: incidence 3-5% per transfusion

›Alloimmunization rates

›Overall RBC alloimmunization: 1-2% of transfused general patients

›SCD patients: 18-36% alloimmunization rate lifetime

›Ethnic donor-recipient antigen mismatch contributes substantially

›Mortality and morbidity

›Overall DHTR mortality: < 1% in general population

›Hyperhemolysis syndrome mortality: up to 5-15% reported

›SCD with hyperhemolysis: case fatality reported at individual centers

›Complications frequency

›Acute kidney injury in approximately 20% of severe cases

›Acute chest syndrome in 15-30% of SCD-associated DHTR

Pathophysiology

›Immune mechanism

›Anamnestic antibody response

›Prior sensitization via transfusion or pregnancy

›Alloantibody becomes undetectable in 10-50% of cases within months to years

›Re-exposure to cognate antigen triggers rapid IgG boosting (anamnestic response)

›Antibody titer rises over 3-7 days

›Extravascular hemolysis (predominant mechanism)

›IgG-coated RBCs recognized by splenic and hepatic macrophage Fc receptors

›Phagocytosis in reticuloendothelial system

›Indirect bilirubin released from heme catabolism

›Intravascular hemolysis (less common, seen in complement activation)

›IgM or complement-fixing IgG activates classical complement pathway

›Membrane attack complex lyses RBC directly

›Hemoglobin released into plasma, then filtered into urine

›Hyperhemolysis mechanism

›Bystander destruction

›Autologous (patient's own) RBCs destroyed alongside transfused cells

›Total hemoglobin falls below pretransfusion level

›Mechanism incompletely understood: macrophage hyperactivation, complement dysregulation

›Antibody-negative DHTR

›Approximately one-third of confirmed DHTR cases lack identifiable new antibody

›Alternative complement pathway activation proposed

›Cytokine-mediated macrophage activation

›Erythropoiesis suppression

›Cytokines from hemolysis suppress marrow response

›Reticulocytopenia during active hemolysis

›Implicated antibody systems

›Most common alloantibodies

›Rh system: anti-E, anti-c, anti-D, anti-C, anti-e

›Kell system: anti-K (most immunogenic non-ABO antigen)

›Kidd system: anti-Jka, anti-Jkb (prone to evanescence)

›Duffy system: anti-Fya, anti-Fyb

›MNS system: anti-S, anti-s

Therapeutic Considerations

›Treatment rationale

›Avoid transfusion as cornerstone of management

›Additional RBCs provide more antigen substrate for antibody-mediated destruction

›Worsens hyperhemolysis in a feed-forward mechanism

›Evidence level: Class I expert consensus

›IVIg mechanism

›Saturates macrophage Fc receptors reducing phagocytosis of IgG-coated RBCs

›Also modulates cytokine production and B-cell function

›ASH 2020 Guidelines: recommended for severe hyperhemolysis

›Corticosteroid mechanism

›Reduces macrophage activation and phagocytic activity

›Downregulates complement and cytokine production

›Synergistic with IVIg in macrophage suppression

›Eculizumab mechanism

›Anti-C5 monoclonal antibody blocking terminal complement

›Prevents membrane attack complex formation on RBC surface

›Particularly effective in complement-mediated hyperhemolysis

›Case series and retrospective data support use; no RCT available

›Prevention strategies

›Extended antigen matching

›ASH 2020 recommends minimum Rh (C/c, E/e) and K matching for all SCD patients

›Extended matching (Jk, Fy, MNS) reduces alloimmunization further

›RBC genotyping preferred over serology for definitive phenotyping

›Transfusion record centralization

›All identified alloantibodies must be documented in accessible central database

›Patient carries antibody identification card at all times

›Rituximab as secondary prevention

›B-cell depletion prevents new alloantibody formation

›Used after acute episode in patients requiring future transfusions

›Leukoreduction and CMV-negative blood

›Universal leukoreduction standard in high-risk populations

›CMV-negative preferred for immunocompromised patients

11Patient Discharge Instructions/pdi41

copy discharge instructions

›Discharge teaching for DHTR

›What is a delayed hemolytic transfusion reaction

›Your immune system made antibodies against proteins on the transfused red blood cells

›These antibodies caused the transfused cells to be destroyed

›This can happen 3-30 days after receiving a blood transfusion

›Why future blood transfusions require special precautions

›You have been identified as having an antibody to blood cell proteins

›Future transfusions must use specially matched blood

›Always tell healthcare providers about this before any procedure or surgery

›Antibody identification card

›Carry your antibody card at all times

›Show this card to any emergency room, surgeon, or doctor who may need to give you blood

›The card lists the specific antibody that caused your reaction

›Blood banks need this information to find safe blood for you

›Medications after discharge

›Take all prescribed medications as directed

›Complete the full course of steroids if prescribed; do not stop suddenly

›Folic acid supplement daily as directed

›Iron supplementation only if specifically prescribed

›Follow-up instructions

›Blood test follow-up

›Repeat blood count and hemolysis tests in 48-72 hours as arranged

›Follow-up with hematology within 1 week

›Ongoing antibody testing 1-3 months after transfusion

›Recovery expectations

›Most mild reactions resolve within 1-2 weeks

›Fatigue and mild jaundice may persist for up to 2-3 weeks

12References/r40

Guidelines and key sources

›Primary society guidelines

›American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Transfusion Support

›Chou ST, Alsawas M, Fasano RM, et al.

›Blood Advances. 2020

›PMCID: PMC6988392

›NHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report 2014

›National Heart, Lung, and Blood Institute

›Comprehensive evidence review for SCD management

›Hendrickson JE, Fasano RM. Management of Hemolytic Transfusion Reactions

›Hematology: American Society of Hematology Education Program. 2021

›PMID: 34889404

Landmark studies and reviews

›Key references

›Delaney M, Wendel S, Bercovitz RS, et al. Transfusion Reactions: Prevention, Diagnosis, and Treatment

›Lancet. 2016

›PMID: 27083327

›Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic Transfusion Reactions

›New England Journal of Medicine. 2019

›DOI: 10.1056/NEJMra1802338

›Carson JL, Triulzi DJ, Ness PM. Indications for and Adverse Effects of Red-Cell Transfusion

›New England Journal of Medicine. 2017

›DOI: 10.1056/NEJMra1612789

›Tormey CA, Hendrickson JE. Transfusion-Related Red Blood Cell Alloantibodies: Induction and Consequences

›Blood. 2019

›PMID: 30808636

Pediatric and SCD-specific references

›Pediatric and SCD literature

Learn More: Delayed Hemolytic Transfusion Reaction→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.